Back to results
US 9,005,982 B2Granted
Biomarkers associated with autoimmune diseases of the lung
AssigneeThe Regents of the University of California
InventorsMark S. Anderson, Anthony K. Shum
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.
Claims15
A method for assessing whether a mammalian patient has or is predisposed to an interstitial lung disease (ILD), said method comprising:
- a) performing an antibody-based assay to quantitate lung autoantigen-reactive autoantibodies in a biological sample from the patient, wherein the lung autoantigen is a long palate, lung, and nasal epithelium carcinoma-associated protein 1 (LPLUNC1) or a LPLUNC1-like protein comprising the amino acid sequence at least 70% identical to SEQ ID NO:2;
- and
- b) detecting an elevated level of the lung autoantigen-reactive autoantibodies in said biological sample as compared to a control biological sample thereby determining the patient has ILD or a predisposition to ILD.
Dependencies are inferred from the claim text.